| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anti-HIV Agents | 19 | 2019 | 2209 | 1.23 | Why? |
| Plague | 2 | 2018 | 155 | 1.14 | Why? |
| HIV Infections | 35 | 2020 | 11620 | 0.94 | Why? |
| Hepatitis C, Chronic | 4 | 2018 | 973 | 0.91 | Why? |
| France | 34 | 2021 | 12074 | 0.79 | Why? |
| HIV-1 | 14 | 2019 | 3365 | 0.73 | Why? |
| Cost-Benefit Analysis | 6 | 2018 | 2259 | 0.71 | Why? |
| Hepatitis C | 6 | 2018 | 1514 | 0.64 | Why? |
| Substance Abuse, Intravenous | 2 | 2018 | 411 | 0.63 | Why? |
| HIV Protease Inhibitors | 6 | 2019 | 434 | 0.63 | Why? |
| Blood Specimen Collection | 1 | 2020 | 387 | 0.61 | Why? |
| Drug Resistance, Viral | 8 | 2021 | 1083 | 0.57 | Why? |
| Harm Reduction | 1 | 2018 | 392 | 0.53 | Why? |
| Enterobacteriaceae | 1 | 2017 | 395 | 0.52 | Why? |
| Darunavir | 4 | 2018 | 477 | 0.49 | Why? |
| Diarylquinolines | 3 | 2018 | 90 | 0.49 | Why? |
| Cytomegalovirus | 1 | 2018 | 600 | 0.48 | Why? |
| Papillomavirus Vaccines | 1 | 2018 | 405 | 0.48 | Why? |
| Enterobacteriaceae Infections | 1 | 2017 | 529 | 0.45 | Why? |
| Anti-Retroviral Agents | 4 | 2019 | 1099 | 0.45 | Why? |
| Antiretroviral Therapy, Highly Active | 6 | 2019 | 952 | 0.44 | Why? |
| Raltegravir Potassium | 3 | 2019 | 132 | 0.44 | Why? |
| Tenofovir | 4 | 2019 | 449 | 0.42 | Why? |
| Drug Resistance, Multiple, Viral | 1 | 2009 | 37 | 0.41 | Why? |
| Sputum | 2 | 2017 | 1720 | 0.41 | Why? |
| HIV Protease | 3 | 2019 | 86 | 0.40 | Why? |
| Pyrrolidinones | 1 | 2009 | 66 | 0.40 | Why? |
| Health Care Costs | 4 | 2018 | 1007 | 0.40 | Why? |
| gag Gene Products, Human Immunodeficiency Virus | 3 | 2019 | 95 | 0.40 | Why? |
| Papillomavirus Infections | 1 | 2018 | 861 | 0.38 | Why? |
| Siphonaptera | 2 | 2018 | 21 | 0.38 | Why? |
| Viral Load | 15 | 2021 | 15850 | 0.36 | Why? |
| Ritonavir | 6 | 2021 | 4212 | 0.36 | Why? |
| Cerebral Small Vessel Diseases | 2 | 2019 | 89 | 0.35 | Why? |
| Yersinia pestis | 2 | 2018 | 58 | 0.35 | Why? |
| Interferon beta-1a | 2 | 2021 | 316 | 0.35 | Why? |
| Tuberculosis, Multidrug-Resistant | 3 | 2018 | 433 | 0.35 | Why? |
| Hemorrhagic Fever, Ebola | 2 | 2017 | 1475 | 0.33 | Why? |
| Tuberculosis, Pulmonary | 1 | 2017 | 1171 | 0.33 | Why? |
| Antiviral Agents | 11 | 2021 | 41703 | 0.33 | Why? |
| Models, Theoretical | 7 | 2021 | 6659 | 0.33 | Why? |
| Emtricitabine | 2 | 2017 | 202 | 0.32 | Why? |
| Antitubercular Agents | 3 | 2018 | 775 | 0.32 | Why? |
| AIDS Serodiagnosis | 2 | 2017 | 64 | 0.31 | Why? |
| Markov Chains | 2 | 2018 | 502 | 0.31 | Why? |
| Pyrimidinones | 1 | 2006 | 76 | 0.30 | Why? |
| Pneumocystis carinii | 2 | 2018 | 205 | 0.30 | Why? |
| Paris | 6 | 2021 | 1287 | 0.30 | Why? |
| Quality-Adjusted Life Years | 2 | 2018 | 511 | 0.29 | Why? |
| Pyridazines | 2 | 2019 | 86 | 0.28 | Why? |
| Anti-Bacterial Agents | 8 | 2019 | 10083 | 0.26 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.26 | Why? |
| Hospital Costs | 1 | 2006 | 274 | 0.26 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2017 | 3388 | 0.25 | Why? |
| Pneumonia, Pneumocystis | 2 | 2018 | 322 | 0.25 | Why? |
| CD4 Lymphocyte Count | 8 | 2019 | 1517 | 0.25 | Why? |
| Atovaquone | 2 | 2018 | 19 | 0.24 | Why? |
| Homosexuality, Male | 4 | 2019 | 1158 | 0.23 | Why? |
| Humans | 104 | 2021 | 930598 | 0.23 | Why? |
| Sustained Virologic Response | 3 | 2018 | 378 | 0.23 | Why? |
| Models, Economic | 2 | 2018 | 316 | 0.23 | Why? |
| HIV Envelope Protein gp41 | 2 | 2019 | 153 | 0.22 | Why? |
| Cross Infection | 3 | 2017 | 8675 | 0.22 | Why? |
| Hepatitis B | 3 | 2017 | 888 | 0.22 | Why? |
| Adult | 50 | 2021 | 244371 | 0.21 | Why? |
| Hyperbilirubinemia | 1 | 2020 | 81 | 0.21 | Why? |
| Antimicrobial Stewardship | 2 | 2019 | 931 | 0.20 | Why? |
| Models, Statistical | 1 | 2017 | 5312 | 0.20 | Why? |
| Female | 60 | 2021 | 380317 | 0.20 | Why? |
| Male | 62 | 2021 | 367725 | 0.20 | Why? |
| Travel | 6 | 2020 | 7220 | 0.20 | Why? |
| Silicones | 1 | 2019 | 26 | 0.20 | Why? |
| Heterosexuality | 2 | 2017 | 148 | 0.20 | Why? |
| Cytochromes b | 1 | 2018 | 23 | 0.19 | Why? |
| Rilpivirine | 1 | 2019 | 65 | 0.19 | Why? |
| Tuberculoma, Intracranial | 1 | 2018 | 7 | 0.19 | Why? |
| Middle Aged | 48 | 2021 | 270681 | 0.19 | Why? |
| Jaundice | 1 | 2020 | 114 | 0.19 | Why? |
| Actinomycosis | 1 | 2018 | 17 | 0.19 | Why? |
| Transsexualism | 1 | 2019 | 43 | 0.19 | Why? |
| Blood | 1 | 2020 | 274 | 0.19 | Why? |
| Spinal Cord Compression | 1 | 2018 | 35 | 0.19 | Why? |
| Emtricitabine, Rilpivirine, Tenofovir Drug Combination | 1 | 2018 | 3 | 0.19 | Why? |
| Mucosal-Associated Invariant T Cells | 1 | 2021 | 170 | 0.19 | Why? |
| Interleukin-18 | 1 | 2021 | 328 | 0.19 | Why? |
| Heterocyclic Compounds, 3-Ring | 2 | 2019 | 275 | 0.19 | Why? |
| Paraplegia | 1 | 2018 | 38 | 0.18 | Why? |
| Ribavirin | 1 | 2006 | 1182 | 0.18 | Why? |
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 39 | 0.18 | Why? |
| Guinea | 2 | 2017 | 228 | 0.18 | Why? |
| Madagascar | 1 | 2018 | 197 | 0.18 | Why? |
| Nurse Clinicians | 1 | 2019 | 92 | 0.18 | Why? |
| Nitroimidazoles | 1 | 2018 | 69 | 0.18 | Why? |
| Oxazoles | 1 | 2018 | 75 | 0.17 | Why? |
| Insect Bites and Stings | 1 | 2018 | 63 | 0.17 | Why? |
| Cefazolin | 1 | 2017 | 31 | 0.17 | Why? |
| Tuberculosis, Miliary | 1 | 2018 | 66 | 0.17 | Why? |
| Unsafe Sex | 1 | 2018 | 139 | 0.17 | Why? |
| Fanconi Syndrome | 1 | 2017 | 12 | 0.17 | Why? |
| Thoracic Diseases | 1 | 2018 | 118 | 0.17 | Why? |
| Antifungal Agents | 2 | 2018 | 1828 | 0.17 | Why? |
| Staphylococcal Infections | 2 | 2017 | 1099 | 0.17 | Why? |
| Vaccination | 3 | 2018 | 19050 | 0.17 | Why? |
| Urine | 1 | 2020 | 469 | 0.17 | Why? |
| Fluorenes | 1 | 2017 | 101 | 0.16 | Why? |
| Bacterial Vaccines | 1 | 2018 | 139 | 0.16 | Why? |
| Delayed Diagnosis | 2 | 2017 | 1529 | 0.16 | Why? |
| Multiplex Polymerase Chain Reaction | 3 | 2020 | 1439 | 0.16 | Why? |
| Itraconazole | 1 | 2018 | 135 | 0.16 | Why? |
| Hospitalization | 9 | 2021 | 54280 | 0.16 | Why? |
| Chemoprevention | 2 | 2018 | 585 | 0.16 | Why? |
| Semen | 2 | 2019 | 550 | 0.16 | Why? |
| Rodentia | 1 | 2018 | 235 | 0.16 | Why? |
| Coronavirus Infections | 18 | 2021 | 253789 | 0.16 | Why? |
| Superinfection | 1 | 2021 | 459 | 0.16 | Why? |
| Pneumonia, Viral | 17 | 2021 | 243684 | 0.16 | Why? |
| Cobicistat | 1 | 2017 | 172 | 0.16 | Why? |
| Insect Vectors | 1 | 2018 | 227 | 0.15 | Why? |
| Capsid | 1 | 2017 | 197 | 0.15 | Why? |
| Research Support as Topic | 1 | 2020 | 327 | 0.15 | Why? |
| Penicillins | 1 | 2017 | 132 | 0.15 | Why? |
| Post-Exposure Prophylaxis | 1 | 2020 | 472 | 0.15 | Why? |
| Clinical Trials as Topic | 5 | 2020 | 7330 | 0.15 | Why? |
| Mutation | 7 | 2021 | 12376 | 0.15 | Why? |
| Cell- and Tissue-Based Therapy | 1 | 2020 | 422 | 0.15 | Why? |
| Quinolones | 1 | 2017 | 167 | 0.15 | Why? |
| Atazanavir Sulfate | 1 | 2018 | 213 | 0.15 | Why? |
| Aged, 80 and over | 16 | 2021 | 88759 | 0.15 | Why? |
| Intensive Care Units | 4 | 2020 | 29594 | 0.15 | Why? |
| Severe Acute Respiratory Syndrome | 4 | 2006 | 12361 | 0.15 | Why? |
| Population Groups | 1 | 2017 | 212 | 0.14 | Why? |
| Aged | 30 | 2021 | 215776 | 0.14 | Why? |
| Blood Safety | 1 | 2020 | 459 | 0.14 | Why? |
| Benzimidazoles | 1 | 2017 | 275 | 0.14 | Why? |
| Cohort Studies | 12 | 2021 | 36005 | 0.14 | Why? |
| Public Health Surveillance | 2 | 2018 | 3129 | 0.13 | Why? |
| Disease Outbreaks | 6 | 2020 | 27595 | 0.13 | Why? |
| Double-Blind Method | 3 | 2020 | 5988 | 0.13 | Why? |
| Drug Interactions | 2 | 2019 | 1653 | 0.13 | Why? |
| Epidemics | 3 | 2021 | 6407 | 0.13 | Why? |
| Drug Utilization | 1 | 2019 | 619 | 0.13 | Why? |
| Nose | 1 | 2020 | 1093 | 0.13 | Why? |
| Young Adult | 19 | 2021 | 93724 | 0.13 | Why? |
| High-Throughput Nucleotide Sequencing | 4 | 2019 | 3633 | 0.13 | Why? |
| Probability | 1 | 2017 | 923 | 0.13 | Why? |
| North America | 1 | 2018 | 1400 | 0.13 | Why? |
| Bronchi | 1 | 2020 | 1048 | 0.13 | Why? |
| Hospital Administration | 1 | 2020 | 650 | 0.13 | Why? |
| Drug Therapy, Combination | 7 | 2019 | 7268 | 0.13 | Why? |
| Blood Chemical Analysis | 1 | 2017 | 541 | 0.12 | Why? |
| Sofosbuvir | 1 | 2017 | 518 | 0.12 | Why? |
| Logistic Models | 5 | 2021 | 9089 | 0.12 | Why? |
| Africa | 2 | 2020 | 2986 | 0.12 | Why? |
| Interferon-alpha | 1 | 2021 | 1442 | 0.12 | Why? |
| SARS Virus | 2 | 2006 | 13021 | 0.12 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 1165 | 0.12 | Why? |
| Cefoxitin | 1 | 2011 | 11 | 0.12 | Why? |
| Genotype | 3 | 2018 | 4697 | 0.11 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.11 | Why? |
| Hepacivirus | 2 | 2018 | 1509 | 0.11 | Why? |
| Disease Eradication | 1 | 2018 | 581 | 0.11 | Why? |
| Pandemics | 19 | 2021 | 389249 | 0.11 | Why? |
| Respiratory Mucosa | 1 | 2020 | 1522 | 0.11 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2020 | 1138 | 0.11 | Why? |
| Disease Reservoirs | 2 | 2018 | 1672 | 0.11 | Why? |
| Endocarditis | 1 | 2016 | 368 | 0.11 | Why? |
| Amikacin | 1 | 2011 | 62 | 0.11 | Why? |
| beta-Lactamases | 1 | 2017 | 759 | 0.11 | Why? |
| Nasopharynx | 2 | 2021 | 10224 | 0.11 | Why? |
| Heart Transplantation | 2 | 2018 | 1293 | 0.11 | Why? |
| Hospitals | 5 | 2021 | 11793 | 0.11 | Why? |
| Asia | 1 | 2018 | 2399 | 0.11 | Why? |
| Mycobacterium tuberculosis | 2 | 2017 | 1164 | 0.11 | Why? |
| Neuroimaging | 1 | 2018 | 1106 | 0.11 | Why? |
| Lopinavir | 2 | 2021 | 4308 | 0.11 | Why? |
| Mass Screening | 3 | 2021 | 8005 | 0.11 | Why? |
| Adolescent | 10 | 2020 | 86841 | 0.10 | Why? |
| Minocycline | 1 | 2011 | 101 | 0.10 | Why? |
| Sensitivity and Specificity | 4 | 2020 | 22971 | 0.10 | Why? |
| Nitriles | 2 | 2019 | 1053 | 0.10 | Why? |
| Clinical Laboratory Techniques | 4 | 2020 | 23402 | 0.10 | Why? |
| Homeless Persons | 1 | 2021 | 1171 | 0.10 | Why? |
| Influenza, Human | 1 | 2014 | 10779 | 0.10 | Why? |
| Incidence | 5 | 2021 | 25622 | 0.10 | Why? |
| Attitude | 1 | 2019 | 1481 | 0.10 | Why? |
| Models, Biological | 3 | 2020 | 4907 | 0.10 | Why? |
| Protease Inhibitors | 1 | 2006 | 3630 | 0.10 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.10 | Why? |
| Cost of Illness | 2 | 2017 | 1903 | 0.10 | Why? |
| Sexual and Gender Minorities | 1 | 2019 | 1019 | 0.10 | Why? |
| Alcoholism | 1 | 2017 | 691 | 0.10 | Why? |
| Serologic Tests | 2 | 2020 | 4359 | 0.10 | Why? |
| Prevalence | 7 | 2021 | 25773 | 0.09 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2017 | 861 | 0.09 | Why? |
| Liver Cirrhosis | 2 | 2017 | 1810 | 0.09 | Why? |
| Macrophages | 1 | 2021 | 2784 | 0.09 | Why? |
| Hydroxychloroquine | 3 | 2021 | 12447 | 0.09 | Why? |
| RNA, Viral | 7 | 2021 | 32276 | 0.09 | Why? |
| Mycobacterium Infections, Nontuberculous | 1 | 2011 | 167 | 0.09 | Why? |
| Infection Control | 1 | 2017 | 23131 | 0.09 | Why? |
| Alanine | 3 | 2020 | 5687 | 0.09 | Why? |
| Monocytes | 1 | 2021 | 2978 | 0.09 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.09 | Why? |
| Public Policy | 1 | 2020 | 1894 | 0.09 | Why? |
| Sequence Analysis, RNA | 1 | 2017 | 2290 | 0.09 | Why? |
| Drug Administration Schedule | 3 | 2020 | 2324 | 0.09 | Why? |
| Case-Control Studies | 4 | 2021 | 17671 | 0.08 | Why? |
| Pyrimidines | 2 | 2019 | 1557 | 0.08 | Why? |
| Tablets | 2 | 2018 | 219 | 0.08 | Why? |
| Immunocompromised Host | 2 | 2021 | 5150 | 0.08 | Why? |
| Hand Hygiene | 1 | 2017 | 1493 | 0.08 | Why? |
| Oxazines | 2 | 2019 | 279 | 0.08 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.08 | Why? |
| Interferon Type I | 1 | 2020 | 2789 | 0.08 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.08 | Why? |
| Health Resources | 1 | 2020 | 2592 | 0.08 | Why? |
| Bacteremia | 1 | 2017 | 1372 | 0.08 | Why? |
| Poverty | 1 | 2018 | 2302 | 0.08 | Why? |
| Risk Factors | 9 | 2021 | 71621 | 0.08 | Why? |
| Feces | 1 | 2020 | 4235 | 0.08 | Why? |
| Social Determinants of Health | 1 | 2018 | 1757 | 0.08 | Why? |
| Reverse Transcriptase Inhibitors | 2 | 2018 | 309 | 0.08 | Why? |
| Patient Compliance | 1 | 2016 | 1468 | 0.08 | Why? |
| Prospective Studies | 6 | 2021 | 43301 | 0.08 | Why? |
| Adenosine Monophosphate | 2 | 2020 | 5652 | 0.08 | Why? |
| Piperazines | 2 | 2019 | 445 | 0.07 | Why? |
| Bacterial Infections | 1 | 2019 | 2229 | 0.07 | Why? |
| Coinfection | 4 | 2017 | 6820 | 0.07 | Why? |
| Vulnerable Populations | 1 | 2020 | 3099 | 0.07 | Why? |
| Treatment Outcome | 9 | 2021 | 51732 | 0.07 | Why? |
| Disease Transmission, Infectious | 2 | 2018 | 9044 | 0.07 | Why? |
| Betacoronavirus | 12 | 2020 | 204454 | 0.07 | Why? |
| Respiratory Tract Infections | 2 | 2017 | 6817 | 0.07 | Why? |
| Transients and Migrants | 1 | 2017 | 1468 | 0.07 | Why? |
| Seasons | 1 | 2017 | 4071 | 0.07 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2021 | 3892 | 0.07 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.07 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.07 | Why? |
| Surveys and Questionnaires | 8 | 2019 | 43792 | 0.07 | Why? |
| Diagnosis, Differential | 2 | 2018 | 7220 | 0.07 | Why? |
| European Union | 2 | 2018 | 565 | 0.07 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.07 | Why? |
| Disease Progression | 3 | 2018 | 13580 | 0.06 | Why? |
| Cough | 1 | 2017 | 4891 | 0.06 | Why? |
| Viruses | 1 | 2017 | 2238 | 0.06 | Why? |
| Animals | 5 | 2021 | 78931 | 0.06 | Why? |
| Pyridones | 2 | 2019 | 738 | 0.06 | Why? |
| Population Surveillance | 1 | 2020 | 4967 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 5277 | 0.06 | Why? |
| Physicians | 2 | 2019 | 4214 | 0.06 | Why? |
| Zika Virus Infection | 1 | 2016 | 1920 | 0.06 | Why? |
| Guidelines as Topic | 1 | 2015 | 2844 | 0.06 | Why? |
| Withholding Treatment | 2 | 2020 | 798 | 0.06 | Why? |
| Skin Diseases | 1 | 2019 | 2509 | 0.06 | Why? |
| Retrospective Studies | 12 | 2021 | 105322 | 0.06 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.06 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.06 | Why? |
| Molecular Diagnostic Techniques | 1 | 2018 | 4239 | 0.06 | Why? |
| Costs and Cost Analysis | 1 | 2006 | 694 | 0.06 | Why? |
| Viral Fusion Proteins | 1 | 2006 | 399 | 0.06 | Why? |
| Computer Simulation | 4 | 2019 | 4982 | 0.06 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.06 | Why? |
| Diltiazem | 1 | 2020 | 22 | 0.06 | Why? |
| Sulfonamides | 1 | 2009 | 1294 | 0.05 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.05 | Why? |
| Coercion | 1 | 2020 | 57 | 0.05 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2018 | 5164 | 0.05 | Why? |
| Drug Monitoring | 2 | 2019 | 1408 | 0.05 | Why? |
| Administration, Oral | 2 | 2018 | 2340 | 0.05 | Why? |
| Interleukin-15 | 1 | 2021 | 169 | 0.05 | Why? |
| Quality of Life | 2 | 2018 | 9820 | 0.05 | Why? |
| Airway Remodeling | 1 | 2020 | 111 | 0.05 | Why? |
| Criminal Behavior | 1 | 2019 | 8 | 0.05 | Why? |
| Immunoprecipitation | 1 | 2020 | 300 | 0.05 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.05 | Why? |
| Aggregatibacter actinomycetemcomitans | 1 | 2018 | 8 | 0.05 | Why? |
| Pasteurellaceae Infections | 1 | 2018 | 9 | 0.05 | Why? |
| Diffusion | 1 | 2019 | 73 | 0.05 | Why? |
| Propionibacterium acnes | 1 | 2018 | 19 | 0.05 | Why? |
| Dideoxynucleosides | 1 | 2019 | 92 | 0.05 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.05 | Why? |
| Drug Resistance, Multiple, Bacterial | 2 | 2018 | 1115 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| CD4-CD8 Ratio | 1 | 2019 | 235 | 0.05 | Why? |
| Latvia | 1 | 2018 | 50 | 0.05 | Why? |
| Therapeutic Equivalency | 1 | 2018 | 64 | 0.05 | Why? |
| Luciferases | 1 | 2020 | 378 | 0.05 | Why? |
| Diabetes Complications | 1 | 2011 | 2358 | 0.05 | Why? |
| Time | 1 | 2021 | 631 | 0.05 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.04 | Why? |
| Metabolic Clearance Rate | 1 | 2018 | 110 | 0.04 | Why? |
| Pregnancy | 2 | 2018 | 23879 | 0.04 | Why? |
| Influenza Vaccines | 1 | 2014 | 2941 | 0.04 | Why? |
| Patient Acceptance of Health Care | 1 | 2017 | 5002 | 0.04 | Why? |
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 139 | 0.04 | Why? |
| Thoracic Vertebrae | 1 | 2018 | 97 | 0.04 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.04 | Why? |
| Vaccines | 1 | 2017 | 3692 | 0.04 | Why? |
| Plasma | 2 | 2018 | 1809 | 0.04 | Why? |
| Lamivudine | 1 | 2019 | 210 | 0.04 | Why? |
| Methicillin | 1 | 2017 | 73 | 0.04 | Why? |
| Fungal Proteins | 1 | 2018 | 133 | 0.04 | Why? |
| AIDS-Associated Nephropathy | 1 | 2017 | 18 | 0.04 | Why? |
| Histoplasmosis | 1 | 2018 | 83 | 0.04 | Why? |
| Half-Life | 1 | 2018 | 298 | 0.04 | Why? |
| Hepatitis C Antibodies | 1 | 2017 | 120 | 0.04 | Why? |
| Lung Diseases | 1 | 2011 | 2361 | 0.04 | Why? |
| Bronchoalveolar Lavage | 1 | 2021 | 603 | 0.04 | Why? |
| Drug Synergism | 1 | 2020 | 833 | 0.04 | Why? |
| Picornaviridae | 1 | 2017 | 123 | 0.04 | Why? |
| Nonlinear Dynamics | 1 | 2018 | 177 | 0.04 | Why? |
| Maintenance Chemotherapy | 1 | 2017 | 133 | 0.04 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2017 | 170 | 0.04 | Why? |
| Bone Diseases, Metabolic | 1 | 2017 | 64 | 0.04 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2019 | 647 | 0.04 | Why? |
| Africa, Western | 1 | 2017 | 363 | 0.04 | Why? |
| Quarantine | 2 | 2021 | 18418 | 0.04 | Why? |
| Neutralization Tests | 2 | 2020 | 6698 | 0.04 | Why? |
| Drug Dosage Calculations | 1 | 2018 | 243 | 0.04 | Why? |
| Leukoencephalopathies | 1 | 2019 | 230 | 0.04 | Why? |
| Adenine | 1 | 2019 | 463 | 0.04 | Why? |
| Biological Availability | 1 | 2017 | 388 | 0.04 | Why? |
| Hospitals, University | 2 | 2020 | 4173 | 0.04 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.04 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.04 | Why? |
| China | 2 | 2020 | 50654 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.04 | Why? |
| Europe | 3 | 2018 | 12702 | 0.04 | Why? |
| Immunophenotyping | 1 | 2021 | 1290 | 0.04 | Why? |
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 317 | 0.04 | Why? |
| Interleukin-1beta | 1 | 2021 | 992 | 0.04 | Why? |
| Kenya | 1 | 2018 | 887 | 0.04 | Why? |
| Quebec | 1 | 2017 | 498 | 0.04 | Why? |
| Caribbean Region | 1 | 2016 | 349 | 0.04 | Why? |
| Mental Disorders | 1 | 2018 | 6742 | 0.04 | Why? |
| Interleukin-8 | 1 | 2021 | 964 | 0.04 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.04 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.04 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.03 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 7868 | 0.03 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2018 | 323 | 0.03 | Why? |
| Models, Molecular | 2 | 2019 | 7616 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2020 | 1444 | 0.03 | Why? |
| Chromatography, Liquid | 1 | 2018 | 640 | 0.03 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.03 | Why? |
| Sexual Partners | 1 | 2019 | 612 | 0.03 | Why? |
| Infant | 3 | 2018 | 30274 | 0.03 | Why? |
| Hematologic Tests | 1 | 2019 | 521 | 0.03 | Why? |
| Cross-Sectional Studies | 5 | 2019 | 53120 | 0.03 | Why? |
| Fibrosis | 1 | 2017 | 800 | 0.03 | Why? |
| Interleukin-10 | 1 | 2021 | 1409 | 0.03 | Why? |
| Vero Cells | 2 | 2021 | 14117 | 0.03 | Why? |
| Immunization Schedule | 1 | 2021 | 1305 | 0.03 | Why? |
| Patient Acuity | 1 | 2021 | 1755 | 0.03 | Why? |
| Remission Induction | 1 | 2017 | 950 | 0.03 | Why? |
| Health Services Accessibility | 1 | 2017 | 10697 | 0.03 | Why? |
| Health Planning | 1 | 2020 | 607 | 0.03 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.03 | Why? |
| Africa South of the Sahara | 1 | 2017 | 1335 | 0.03 | Why? |
| Treatment Failure | 1 | 2018 | 2106 | 0.03 | Why? |
| Tandem Mass Spectrometry | 1 | 2018 | 1031 | 0.03 | Why? |
| Regression Analysis | 1 | 2019 | 2484 | 0.03 | Why? |
| Time Factors | 3 | 2020 | 31397 | 0.03 | Why? |
| Fasting | 1 | 2017 | 555 | 0.03 | Why? |
| Flow Cytometry | 1 | 2020 | 2393 | 0.03 | Why? |
| Likelihood Functions | 1 | 2014 | 719 | 0.03 | Why? |
| Infant, Newborn | 2 | 2018 | 23105 | 0.03 | Why? |
| Health Priorities | 1 | 2020 | 959 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.03 | Why? |
| HIV | 1 | 2018 | 1116 | 0.03 | Why? |
| Drug Combinations | 1 | 2021 | 3852 | 0.03 | Why? |
| Adenoviridae | 1 | 2017 | 1151 | 0.03 | Why? |
| Global Health | 3 | 2021 | 13911 | 0.03 | Why? |
| Islam | 1 | 2017 | 545 | 0.03 | Why? |
| Ebolavirus | 1 | 2017 | 834 | 0.03 | Why? |
| Area Under Curve | 1 | 2018 | 2564 | 0.03 | Why? |
| Single-Cell Analysis | 1 | 2021 | 2450 | 0.03 | Why? |
| Sexual Behavior | 1 | 2019 | 1322 | 0.03 | Why? |
| Motivation | 1 | 2020 | 1640 | 0.02 | Why? |
| Viremia | 1 | 2017 | 1020 | 0.02 | Why? |
| Pneumonia, Bacterial | 1 | 2017 | 843 | 0.02 | Why? |
| Middle East | 1 | 2014 | 1418 | 0.02 | Why? |
| Ambulatory Care | 1 | 2006 | 4947 | 0.02 | Why? |
| Community Health Services | 1 | 2018 | 1000 | 0.02 | Why? |
| Clinical Protocols | 1 | 2020 | 2734 | 0.02 | Why? |
| General Practice | 1 | 2017 | 718 | 0.02 | Why? |
| Health Policy | 2 | 2020 | 6242 | 0.02 | Why? |
| Orthomyxoviridae | 1 | 2017 | 1168 | 0.02 | Why? |
| Protein Conformation | 1 | 2019 | 4386 | 0.02 | Why? |
| Vaccines, Synthetic | 1 | 2021 | 3231 | 0.02 | Why? |
| Amides | 1 | 2019 | 1864 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2017 | 1414 | 0.02 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.02 | Why? |
| Patient Isolation | 1 | 2021 | 3182 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2019 | 6049 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.02 | Why? |
| Drug Costs | 1 | 2010 | 313 | 0.02 | Why? |
| Cognitive Dysfunction | 1 | 2018 | 1389 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| Exanthema | 1 | 2016 | 1097 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.02 | Why? |
| Software | 1 | 2018 | 2501 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Rural Population | 1 | 2018 | 2408 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Contact Tracing | 1 | 2006 | 8448 | 0.02 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.02 | Why? |
| Decision Making | 1 | 2020 | 3132 | 0.02 | Why? |
| Fatigue | 1 | 2016 | 2479 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2018 | 3493 | 0.02 | Why? |
| Information Dissemination | 1 | 2020 | 2986 | 0.02 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.02 | Why? |
| Zika Virus | 1 | 2016 | 1924 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2016 | 6543 | 0.02 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.02 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.02 | Why? |
| Patient Safety | 1 | 2018 | 4885 | 0.02 | Why? |
| Thrombocytopenia | 1 | 2016 | 2093 | 0.02 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.02 | Why? |
| Protein Binding | 1 | 2019 | 11430 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.01 | Why? |
| Algorithms | 1 | 2019 | 7346 | 0.01 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.01 | Why? |
| Transplant Recipients | 1 | 2018 | 4982 | 0.01 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.01 | Why? |
| Liver Transplantation | 1 | 2017 | 2864 | 0.01 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.01 | Why? |
| Aircraft | 1 | 2004 | 498 | 0.01 | Why? |
| Health Status Disparities | 1 | 2017 | 4072 | 0.01 | Why? |
| Fever | 1 | 2016 | 7795 | 0.01 | Why? |
| Vietnam | 1 | 2004 | 1665 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Child, Preschool | 1 | 2018 | 36283 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Hospital Mortality | 1 | 2017 | 22087 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |
| Child | 1 | 2018 | 70012 | 0.01 | Why? |